This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in

This promotional video has been developed, organised and funded by CSL Seqirus. The content has been reviewed and approved by the sponsoring company prior to broadcast. GPnotebook has had no input into the content. PBS and Product Information can be found at the bottom of the page.

Promotional content from CSL Seqirus for healthcare professionals in Australia only

Residual CV risk beyond LDL-C: A practical approach for general practice

  • Sponsored

Posted 1 Apr 2026

Join Dr Anita and Associate Professor Adam Nelson as they explore how to identify and best manage patients with residual CV risk beyond LDL-C lowering, as well as looking at a real-world case study.

CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol

Please review Product Information before prescribing. Product Information available at www.tga.gov.au/resources/auspmd/vazkepa or www.cslseqirus.com.au/products.

  • White text "CSL Seqirus" on a red banner.
  • Logo

▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

AU-VZKP-26-0046 | May 2026